Loading...
Loading...
TNXP| Name | Value |
|---|---|
| Revenues | 3.8M |
| Cost of Revenue | 3.9M |
| Gross Profit | -0.1M |
| Operating Expense | 27.2M |
| Operating I/L | -27.3M |
| Other Income/Expense | 0.0M |
| Interest Income | -1.7M |
| Pretax | -27.3M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -27.3M |
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company specializing in discovering, developing, and licensing therapeutics and diagnostics for various human diseases. The company's portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. These products range from biologics targeting organ transplant rejection, autoimmunity, and cancer, to vaccines for smallpox and COVID-19, as well as small molecule drugs for pain management and addiction conditions. With a focus on addressing unmet medical needs, Tonix Pharmaceuticals generates revenue through the development and commercialization of its diverse pipeline of pharmaceutical products.
